Workshops at RESI South

21 Mar

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti

RESI South – March 25-27, 2024 – is more than an opportunity to meet one-on-one with investors and other key players in the life science space. The conference also offers quality workshops on many hot topics relevant to the early-stage space, sponsored by our many great partners. Building a successful startup requires a lot of pieces to be in place, and startup CEOs should take advantage of industry experts to avoid common pitfalls, as demonstrated by these workshops. The live format allows for interactive Q&A and makes the sessions more dynamic.

10 AM ET | Investing in YOU: Personal Wealth Planning for Founders

Integrating Science and Technology to Create Disruptive Innovations

With the recent (if not constant) ups and downs seen in the life science capital markets and banking sector, founders must begin with the entrepreneurial end in mind: a successful liquidity event for both investors and the founder. From deciding the legal structure of your company, to share structure, to tax considerations and estate planning and more, founders need to have a plan from the start. This panel includes experts from banking to wealth management, venture capital, and an entrepreneur.

Presenters:

  • Maria Clarke, CFA, Executive Director and Banker, J.P. Morgan Private Bank
  • Matthew Miessau, Principal, Epidarex Capital
  • Marta New, Founder and CEO, Radyus Research
  • Chris Sarlo, Founder & Wealth Consultant, Life Science Wealth

11 AM ET | Negotiating Term Sheets

What’s Best for the Company and What’s Best for You?

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

Presenters:

  • Brian M. Gordon, Partner, McDermott Will & Emery – Atlanta
  • Jim Tobin, Vice President, Cardiovascular & Metabolism Scientific Innovation, Johnson & Johnson Innovation
  • Sarah Sarb, Associate, McDermott Will & Emery

1 PM ET | Navigating the Startup Incubator, Laboratory, and Equipment Procurement MarketPlace

Startups that need access to incubators, laboratory space, and medical and research equipment have many options today. This workshop will map out how to determine the best opportunities for you and best practices to manage the process of evaluating lab space and procuring equipment. Topics discussed are the current laboratory and startup incubator space business models, equipment choices, and other auxiliary offerings like consulting and introduction to partners. How does a startup determine the best lab model and equipment for your current needs? Understand how to find and locate lab space and then ask the right questions to meet your current and future needs. The main topics to explore are inexperienced realtors with the cookie-cutter preconfigured lab space versus experienced customized midlevel and high-end build-out and the used versus new equipment. The workshop will explain what and where the pivot points are for shelling out the dollars for something new that will enhance and speed up product development and when to save money and go with the used, tried, and true. This workshop will empower you to navigate and make better choices and ask the right questions when choosing your laboratory and equipment providers.

Presenters:

  • Barb Pearlman, Founder & President, CSP & CSL
  • Andrew Lau, General Manager & Director of Operations, CSP & CSL

2 PM ET | Tales from the Road

Biotech and MedTech Innovators on their Fundraising Journey

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges.

Presenters:

  • Greg Mannix, Vice President of International Business Development, Life Science Nation
  • Anthony Desir, Director, Moexa
  • Pepper Landson, CEO, Praetego
  • William Tyler, CEO, Atara Labs, Inc.

3 PM ET | Global Partnering Campaign – Investor Landscape, GTL and CRM/GPC

Once you are ready to embark on your fundraising campaign, how do you know whom to target? What investors are the best fit for you, how do different investors invest and partner, and how do you get in touch with them? Identifying investors, learning about the differences between investor types, accessing a database to provide you with key information to filter your best-fit investors, and finally, using a CRM to manage your fundraise are critical to an efficient and successful fundraise.

Presenters:

  • Claire Jeong, VP, Investor Research & Asia Business Development, Life Science Nation
  • Karen Deyo, VP of Product, Israel Business Development, Life Science Nation

4 PM ET | It All Starts with a Story

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch, or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice, and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story about your company and technology, you are on the right track to building successful relationships.

Presenters:

  • Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
  • Greg Mannix, VP of International Business Development, Life Science Nation

Sign up to participate at RESI South and learn more about sponsoring workshops at future events!

RESI-South-2024_02062024.

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Hot Investor Mandate: CVC Fund Invests in Medtech & Digital Health Technologies That Address Chronic Conditions and Areas of Unmet Medical Need

21 Mar

A corporate venture capital fund invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the corporation’s goal of helping save 1M lives annually by 2030. This fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm currently has 12 portfolio companies and is actively deploying capital. 
 
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training. 
 
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Venture Fund Seeks Pre-Seed to Series A Investments in USA-Based Therapeutics, Diagnostics, and Data-Driven Companies

21 Mar

An early-stage venture capital firm was founded in 2010 and based in the US. The firm is a generalist fund, looking to expand its footprint in life sciences, specifically data, diagnostics, and therapeutics in oncology.  The firm focuses on Pre-Seed, Seed, and Series A investments. Typical check size ranges from $500k-5M USD, leading rounds. The firm focuses on companies in the US. 
 
The firm invests in data, diagnostics and therapeutics, with a strong preference in oncology. The firm was one of the first institutional investors in Tempus, an AI-driven data and diagnostics platform, and Pathos, an AI-driven clinical stage therapeutics platform in oncology.  Within therapeutics, companies should be pre-Phase II and for data and diagnostics companies, in-development stages. 
 
The firm does not require to take a board or observer seat but often will. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Taiwan VC Invests Up to $10M in Technology-Based Companies Addressing Chronic Disease Management, Oncology, Metabolic Diseases and More 

21 Mar

A venture capital firm founded and headquartered in Taiwan is overall focused on investing in biotech and tech-related companies such as AI, biotech, medical device, pharma, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Central Eastern Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S. 
 
The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on are chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data. 
 
The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: VC Headquartered in China Invests $5-10M, Focusing on Seed Stage Therapeutics and Growth Stage Diagnostics Across the Globe

21 Mar

A venture capital firm specialized in life sciences and medical technology, managing both RMB and USD funds with a total size of $1.5B, is operated by a professional team with diversified and profound industry backgrounds, having made over 90 investments with high growth potential since 2014. Typical Allocations Size of the firm’s RMB fund is 30MM-150MM in RMB, and up to 200MM in RMB; for the USD fund, the firm invests $5-10MM+ on average, and up to $20MM. 
 
The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. Especially, the firm is interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. The firm is not interested in small molecules nor antibodies for now. 
 
The firm prefers companies that are tech-driven, commercially viable and are able to solve the real problem. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Presenting the RESI South Program Guide

14 Mar

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) presents the Program Guide for RESI South, taking place in person on Monday, March 25, followed by two days of virtual partnering on March 26-27! This hybrid conference will take place at The Whitley Buckhead Hotel in Atlanta, and we are excited to release the digital version of the RESI Program Guide. Check out the various panelists, exhibitors, and workshops participating in this RESI. In addition, make sure to check out the Innovator’s Pitch Challenge, where over 40 companies will pitch to a panel of investor judges.

RESI-South-Cover

It is not too late to attend if you seek capital investment or licensing opportunities. Register today.

RESI-South-2024_02062024.

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Hot Investor Mandate: USA-Based VC Invests $10-40M in Novel Therapeutics Companies Across All Modalities and Indications

14 Mar

An investment firm headquartered in the US focuses on investing in public and private healthcare companies. In terms of early-stage companies, the firm is stage-agnostic with check sizes ranging from $10M-40M USD at the Series A round. The firm has a heavy bias for U.S.-based companies but may look at the EU. 
 
The firm is stage-, modality-, and indication-agnostic. For therapeutics, interests include genetically driven assets and novel biology/target/MoA. The firm typically does not invest in companies, for example, vaccine or immune-oncology companies unless there is clinical or human data. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.